Squarepoint
TGTX icon

Squarepoint’s TG Therapeutics TGTX Stock Holding History

Squarepoint’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.44M Buy
+117,300
New +$4.8M 0.01% 1387
2025
Q4 		– Sell
-13,800
Closed -$499K – 4887
2025
Q3 		$499K Buy
13,800
+2,500
+22% +$82.3K ﹤0.01% 3234
2025
Q2 		$407K Sell
11,300
-400
-3% -$14.9K ﹤0.01% 3442
2025
Q1 		$461K Sell
11,700
-48,100
-80% -$1.62M ﹤0.01% 3378
2024
Q4 		$1.8M Buy
+59,800
New +$1.72M ﹤0.01% 2522

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Squarepoint's TGTX Position: Q2 2026 in Review

Squarepoint reduced its TG Therapeutics (TGTX) stake by 68% in Q2 2026, selling an estimated $14.2M and leaving 166,975 shares worth $9.17M. The position accounts for 0.01% of the portfolio, ranked #1154.

Squarepoint first reported a position in TGTX in Q4 2015 and has held it in 23 quarters since. The position peaked at $25.4M in Q4 2025. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Squarepoint held 166,975 shares of TG Therapeutics worth $9.17M as of Q2 2026.
  • Squarepoint sold 346,838 TG Therapeutics shares in Q2 2026, an estimated $14.2M.
  • TG Therapeutics made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1154 holding.
  • Squarepoint first reported a position in TG Therapeutics in Q4 2015 and has held it in 23 quarters since.
  • Squarepoint's TG Therapeutics position peaked at $25.4M in Q4 2025.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.